Supernus Pharmaceutical (SUPN) 'Doubles' on Tentative FDA Approval
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) continues to rip higher following tentative FDA approval for Trokendi XR. Shares have now doubled.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein sees 'an entry point in our top-pick' chemical stock
- This name is "a later-cycle beneficiary of the AI spending cycle": Goldman
- This cyberstock is best-positioned in a post-quantum world
Create E-mail Alert Related Categories
Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
